Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamminga, Menno, de Wit, Sanne, Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Terstappen, Leon W. M. M., Groen, Harry J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://www.ncbi.nlm.nih.gov/pubmed/31291995
http://dx.doi.org/10.1186/s40425-019-0649-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://www.ncbi.nlm.nih.gov/pubmed/31291995
http://dx.doi.org/10.1186/s40425-019-0649-2

Ejemplares similares